Genmab News and Activities
Presence
Genmab is a biotechnology company that develops antibody medicines for cancer and other serious diseases. It provides drug discovery and development services for patients, healthcare providers, and pharmaceutical partners.
Genmab products and services overview:
- Antibody medicines
- Cancer treatments
- Drug discovery
- Clinical development
- Research partnerships
- Immunotherapy solutions
Revenue: ~$3 billion
Employees: 2,600
Headquarters: Copenhagen, Denmark
Genmab is one of the...
Genmab is a company listed under the stock ticker GMAB (DK).
Genmab has a direct presence in 4 countries.Genmab has 4 subsidiaries including Genmab Europe, Genmab Japan and Genmab USA.
Acquisition, funding and merger involving Genmab.
- Genmab has acquired Merus Bio (posted on December 30 2025).
- Genmab has announced the acquisition of Merus Bio (posted on October 27 2025).
- Genmab has acquired Merus (posted on September 30 2025).
Executives
View the org chart displaying its 73 main executives
Most searched biographies at Genmab
- Jan Van de Winkel, President and Chief Executive Officer
- Pernille Erenbjerg, Vice Chairman of the Board
- Rolf Hoffmann, Director
Popular executive movements at Genmab
- Robert Doornbos has joined the company as Vice President, Head of Chemistry, Manufacturing and Controls Product Development (posted on April 3 2026).
- Margarida Duarte has joined the company as General Manager, Europe and Emerging Markets (posted on April 3 2026).
Create your alert
to follow the executive moves at Genmab.
Biotechnology
Genmab has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by Genmab
- Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - Genmab A/S
- Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress - Genmab A/S
- Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer - Genmab A/S
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 - Genmab A/S
- Genmab A/S has published its Articles of Association - Genmab A/S
- Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab - Genmab A/S
- Passing of Genmab A/S’ Annual General Meeting - Genmab A/S
- Completion of Share Buy-back Program - Genmab A/S
- Transactions in Connection with Share Buy-back Program - Genmab A/S
- Genmab A/S has published its Articles of Association - Genmab A/S
- View more press releases Close
Social media about Genmab
- Genmab on Wikipedia, Google News & Yahoo Finance
- Genmab on LinkedIn, X (Twitter) & YouTube
